Bristol-Myers Squibb files for approval in Japan of first ever all-oral and interferon- and ribavirin-free hepatitis C treatment.
Stacked announcements of positive study results help mitigate Bristol-Myers Squibb's patent expirations.
A roundup of the day's best performers within the S&P 500, and what their moves mean for investors.
Bristol-Myers Squibb and GlaxoSmithKline both revealed their third quarter earnings recently, and what each company released shows a lot about where these firms are headed
A clinical research study supported by Bristol-Myers Squibb finds a triple drug therapy that is effective in treating hepatitis C in about 90% of patients.
A study by Harris Interactive digs into the American psyche and discovers which five diseases terrify Americans the most. While you may have seen number one coming a mile away, the other answers may surprise you.
25.3 million people in the U.S. are diabetic and another 79 million are exhibiting symptoms of pre-diabetes, yet one steadfast admission by actor Tom Hanks could improve type 2 diabetes awareness by more than the Centers for Disease Control and Prevention had ever hoped.
Management isn't always the best to listen to.
Bristol-Myers Squibb's Yervoy is succeeding as a first-line treatment in melanoma. But can the drug hold off new competitors and expand its label to become a blockbuster drug?
Three ominous warning signs could signal a dramatic reversal is on the way for the biotech sector.